// App-Quantinova.ai

N803 : Accelerated infusions of biosimilar infliximab are safe and well tolerated and monitoring post-infusion is not required

Researchers

Presenter

  • K. Robinson

Principal Investigators

  • A. Wright

  • L. Marshall

  • A. Lobo

Medical Centers

  • Sheffield Teaching Hospitals NHS Trust, Cardiology, Sheffield, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

  • Infliximab Biosimilar

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved